Save 50% on your Social Media Week pass! Join leading brands and agencies in NYC this April 9–11 to learn about emerging trends, tools and strategies. Register now—savings expire Dec. 11.
The Food and Drug Administration’s position on acetaminophen, the active ingredient in Tylenol, is giving parent company Johnson & Johnson a branding headache, according to researcher YouGov.
The firm, whose BrandIndex polls 5,000 U.S. adults daily on brand perception, found Tylenol’s negative buzz grew in a very short amount of time.
On June 25, the brand’s buzz score-which is rated on a scale of 100 to -100 and calculated by subtracting negative feedback from positive-was 38.9
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in